Skip to content

IP Estate

The Evox portfolio includes granted and pending applications in the world's major pharmaceutical markets, including USA, Europe, Japan, China as well as various other jurisdictions. In addition to the patent portfolio Evox also safeguards its intellectual property by the maintenance of several trademarks, copyrights, and trade secrets which together form broad and deep protection for the company's intellectual assets.

Key aspects of Evox’s intellectual property portfolio include:

  • Exosomes for delivery of nucleic acid-based agents - including mRNA, siRNA, antisense oligonucleotides, and CRISPR technologies.
  • Exosomes for delivery of protein therapeutics - including antibodies, receptors and enzyme replacement therapies.
  • Tailored targeting technology - directing exosomes to tissues and organs of interest.
  • Proprietary exosome manufacturing and purification methods – cellular engineering technology, upstream optimization and downstream processing.

In addition to actively pursuing and protecting our ground-breaking exosome therapeutics we are always looking for opportunities to complement our growing IP estate. Please get in touch: bd@evoxtherapeutics.com.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.